Article
BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
PloS one - 1 Jan 2016
Nam Soo Kyung, Yun Sumi, Koh Jiwon, Kwak Yoonjin, Seo An Na, Park Kyoung Un, Kim Duck-Woo, Kang Sung-Bum, Kim Woo Ho, Lee Hye Seung
Abstract excerpt
BACKGROUND: Anti-EGFR antibody-based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations--including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification--are associated with the mechanisms underlying the development of resistance to anti-EGFR therapy. The aim of our study was to investigate the frequencies and clinical implications of these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
